#biotech

📰News 📈 Stocks

CRSP and VKTX: Two Biotech Stocks Poised for Growth in 2027

September 12, 2026 (13 days ago)

CRISPR Therapeutics and Viking Therapeutics offer strong long-term potential as clinical milestones and revenue recognition cycles align for 2027 growth.

CRSP VKTX

🌍 AMERICAS Read More →

📰News 📈 Stocks

Champions Oncology Revenue Climbs 9% as Q1 EBITDA Hits $671,000

September 12, 2026 (13 days ago)

Champions Oncology posted a 9% revenue increase to $15.2 million in Q1 fiscal 2027, driven by improved service margins and a surge…

CSBR

🌍 AMERICAS Read More →

📰News 📈 Stocks

Royalty Pharma Limits Losses After Novartis Pelacarsen Phase 3 Trial Failure

September 12, 2026 (13 days ago)

Royalty Pharma pivots to Spinraza royalties to recoup its $500 million investment after the Phase 3 failure of Novartis's cardiovascular drug, pelacarsen.

RPRX IONS NVS

🌍 AMERICAS Read More →

📰News 📈 Stocks — 📈 Bullish

Kiniksa Pharmaceuticals Eyes Breakout After Strong Quarterly Revenue Beat

September 10, 2026 (15 days ago)

Kiniksa Pharmaceuticals shares gain momentum as strong quarterly revenue figures push the stock toward a new buy point, highlighting the company's growth…

🌍 NORTH AMER Read More →

📰News 📈 Stocks — 📈 Bullish

Goldman Sachs Adds Vertex Pharmaceuticals to Conviction List Amid Pipeline Push

September 10, 2026 (15 days ago)

Vertex Pharmaceuticals earns a spot on Goldman Sachs' conviction list as the biotech leverages its dominant cystic fibrosis cash flow to fund…

🌍 NORTH AMER Read More →

📰News 📈 Stocks

Teladoc and Recursion Pharmaceuticals Face Dim Outlooks Amid Growth Struggles

September 10, 2026 (16 days ago)

Investors should avoid Teladoc and Recursion Pharmaceuticals as both companies grapple with declining revenue, stiff competition, and unproven business models in a…

LLY NVO BMY

🌍 NORTH AMER Read More →

📰News 📈 Stocks

Goldman Sachs Identifies Two Biotech IPOs With Over 75% Upside Potential

September 10, 2026 (16 days ago)

Goldman Sachs analyst Salveen Richter initiates coverage on Latigo Biotherapeutics and Braveheart Bio, citing significant clinical potential and large addressable markets for…

LTGO

🌍 NORTH AMER Read More →

📰News 📈 Stocks

Dow Futures Slip 366 Points as Amgen Slump Weighs on Price-Weighted Index

September 10, 2026 (16 days ago)

Amgen's 6% premarket decline drags the Dow Jones lower, while Novartis trial failures trigger a broader sell-off in related biotech stocks including…

AMGN DJIA

🌍 NORTH AMER Read More →

📰News 📈 Stocks

Novartis Shares Slump 13% on Failed Clinical Trial, Amgen Drops 9%

September 10, 2026 (16 days ago)

Novartis shares plummeted 13% following a failed clinical trial for del-desiran, while Amgen shares dropped 9% on contagion fears, pressuring the Dow…

AMGN DJIA

🌍 NORTH AMER Read More →

📰News 📈 Stocks — 📉 Bearish

Novartis Shares Plunge 12% Following Dual Phase 3 Clinical Trial Failures

September 9, 2026 (16 days ago)

Novartis shares fell 12.57% following two major clinical trial disappointments, triggering a broader sell-off in biotech partners Ionis Pharmaceuticals and Royalty Pharma.

🌍 NORTH AMER Read More →

📰News 📈 Stocks — 📉 Bearish

BioNTech Shares Slip 1.2% as BMO Capital Downgrades Stock to Market Perform

September 9, 2026 (16 days ago)

BioNTech faces pressure as BMO Capital downgrades the stock, citing lower COVID-19 vaccine demand and reduced 2026 revenue guidance, while the company…

🌍 EUROPE Read More →

📰News 🌐 Macro — 📊 Neutral

CFTC Penalties Highlight Insider Trading Risks in Emerging Prediction Markets

September 9, 2026 (16 days ago)

As prediction markets expand into biotech, pharma companies must update compliance frameworks to prevent third-party leaks and insider trading on sensitive clinical…

🌍 NORTH AMER Read More →